Dec 4 (Reuters) - Stoke Therapeutics STOK.O:
STOKE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME
STOKE THERAPEUTICS INC - PHASE 3 REGISTRATION STUDY UPDATE EXPECTED BY YEAR-END
Source text: ID:nBw6M4lMYa
Further company coverage: STOK.O
((Reuters.Briefs@thomsonreuters.com;))